Objective: To investigate whether daily supplementation with the probiotic Bifidobacteria (
B. breve) reduces infection-related mortality in extremely low birth weight (ELBW) and very low birth weight (VLBW) premature infants.
Patients and Methods: We conducted a retrospective investigation of the effect of
B. breve supplementation on two groups of premature infants; one group received
B. breve supplementation and one did not. The non-supplemented group was comprised of 309 premature infants (126 ELBW and 183 VLBW) who were admitted to the Neonatal Intensive Care Unit (NICU) during a 6-year period (1994-1999). The
B. breve supplemented group was comprised of 434 premature infants (210 ELBW and 224 VLBW) who were admitted to the NICU during a different 6-year period (2001-2006). Infants in the supplemented group were given
B. breve at a daily dose of 1 x 109 CFU (M-16V, Morinaga, Japan, freeze-dried preparation). The
B. breve supplement was dissolved in either raw mother's milk or in a mixture of preterm formula and mother's milk, starting several hours after birth and continuing until discharge from the NICU. The non-supplemented infants were fed a similar regimen that did not include,
B. breve supplementation. Infection-related mortality was defined as the death of an infant after 3 days of age after a diagnosis of severe infection or sepsis based on clinical features and laboratory data. The infants were diagnosed irrespective of blood culture results when abnormalities of white blood cell counts, differentials, and serial levels of CRP≥2.0mg/dl were found.
Results: The infection related mortality was significantly reduced in ELBW infants and in all infants weighing less than 1,500g at birth in the
B. breve supplemented group.
Conclusion: Daily supplementation with
B. breve in infants weighing less than 1,500g at birth was a very effective method for reducing the infection-related mortality in these premature infants.
View full abstract